The first consumer cancer app that is clinically proven to raise Quality of Life by 14.3%*
How does the CancerLife app improve quality of life for cancer patients and survivors?
Digital supportive care for those impacted by cancer
One of the biggest challenges in cancer care today is managing symptoms. Doctors are focused on the tumor and not the patient. The patients are overwhelmed with
an average of 12 symptoms at a time. Quality of life suffers as these issues linger. Patients need their own digital companion to help them through their journey.
AVERAGE SYMPTOM BURDEN PER PERSON
FOR THESE ISSUES
EXPERIENCE CHRONIC PAIN
Digital supportive care for those impacted by cancer.
CancerLife is a caner app that has been scientifically validated to raise the Quality of Life in patients across America. By engaging on the CancerLife platform, patients can communicate with fellow patients to find comfort, support and companionship. CancerLife also seamlessly collects patient reported outcome data so that patients can share with their healthcare providers. When sharing their reports with their care management team, patients are able to receive better care and improved physical well-being. As seen in our clinical trial with the John Wayne Cancer Institute, CancerLife can raise Quality of Life by 14.3%.
What is the CancerLife App?
Online Social Support Network (Patients and Survivors)
Patient Reported/ Patient Relevant Outcomes Data Collection
Our fully randomized,
two arm clinical trial.
CancerLife Disclaimer: CancerLife does not treat cancer but is designed to assist you during your journey with social support and promote other healthy behaviors that can positively impact your quality of life. (QOL)
Cancerlife App User Reviews
Here are some details about our study
*Breast cancer patients were recruited online and randomly assigned to receive an introduction to CancerLife’s app. (N= 374 for intervention group; N=125 for control group.) Patients were drawn from various parts of the country and various types of care settings including over 170 different area codes yielding a wide mix of the cancer population. The Welch’s Two Sample t-test was performed first, using R, to measure any statistical difference in these mean scores within each group for each time period through observing the resulting p-values and t-scores. In order to compare the scores of Patients in CancerLife’s program with those in the Control groups, an F-test was performed, to observe if each sample contained the same variance which would make the groups comparable. The difference in scores were then calculated for each individual and Difference in means test were performed using Two Sample t-test to gauge improvements. This test was then repeated to measure the percent improvement in each group, as to record quantifiable improvement value for CancerLife if proven statically significant. All tests were performed at a 5% significance level.